High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
17
07
2020
accepted:
09
06
2021
revised:
06
05
2021
pubmed:
1
7
2021
medline:
11
3
2022
entrez:
30
6
2021
Statut:
ppublish
Résumé
Risk stratification is important for balancing potential risks and benefits of allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies. We retrospectively studied 1119 patients undergoing allogenic-HSCT in a single center for five hematological indications assessing the prognostic role of LDH at admission for survival (OS), progression-free survival (PFS), relapse incidence (RI), and nonrelapse mortality (NRM). In non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), higher than median LDH had an adverse effect on survival. The prognostic significance was strongest in AML, with higher LDH levels having lower 1-and 3-year survival 69.2% vs. 50.8%, P < 0.001 and 51.9% vs. 39.2%, P < 0.001, respectively, reduced 1-and 3-year PFS 62.4% vs. 42.1%, P < 0.001 48% vs. 35.2%, P < 0.001, respectively, higher cumulative incidence of 1-and 3-year NRM 11% vs. 17.3%, p = 0.01 and 15.7% vs. 19.6%, P = 0.04, and higher 1-and 3-year relapse incidence (RI) 26.7% vs. 40.7%, p < .0001 36.2% vs. 40.7%, respectively, P < 0.0001). In multivariate analysis LDH maintained significant prognostic capacity in OS, PFS and RI. These findings in AML, validated in an independent cohort, suggest that LDH is a readily available tool that could be integrated into transplant risk assessments to aid decision-making and identify high-risk patients who may benefit from post-transplant pharmacological or cellular strategies.
Identifiants
pubmed: 34188181
doi: 10.1038/s41409-021-01377-9
pii: 10.1038/s41409-021-01377-9
doi:
Substances chimiques
L-Lactate Dehydrogenase
EC 1.1.1.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2690-2696Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Potdar R, Varadi G, Fein J, Labopin M, Nagler A, Shouval R. Prognostic scoring systems in allogeneic hematopoietic stem cell transplantation: where do we stand? Biol Blood Marrow Transpl. 2017;23:1839–46.
doi: 10.1016/j.bbmt.2017.07.028
Carreras E, Dufour C, Mohty M, Kröger N. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Springer; 2019. pp 77–86.
Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, et al. Classifying cytogenetics in patients with AML in complete remission undergoing allogeneic transplantation: a CIBMTR study. Biol Blood Marrow Transpl. 2012;18:280–8.
doi: 10.1016/j.bbmt.2011.07.024
Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.
doi: 10.1200/JCO.2015.63.3826
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2006;106:2912–9.
doi: 10.1182/blood-2005-05-2004
Elsawy M, Sorror M. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2016;51:1283–1300.
doi: 10.1038/bmt.2016.141
Shouval R, Labopin M, Unger R, Giebel S, Ciceri F, Schmid C, et al. Prediction of hematopoietic stem cell transplantation related mortality- lessons learned from the in-silico approach: a european society for blood and marrow transplantation acute leukemia working party data mining study. PLoS ONE. 2016;11:e0150637.
doi: 10.1371/journal.pone.0150637
Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, et al. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;12:1881–90.
doi: 10.1182/bloodadvances.2019032268
Dimopoulos MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med. 1991;115:931–5.
doi: 10.7326/0003-4819-115-12-931
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33:2863–9.
doi: 10.1200/JCO.2015.61.2267
Kim SJ, Hong JS, Chang MH, Kim JA, Kwak JY, Kim JS, et al. Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. OncoTargets. 2016;7:72033–43.
doi: 10.18632/oncotarget.12459
Schneider RJ, Seibert K, Passe S, Little C, Gee T, Lee BJ 3rd, et al. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer. 1980;46:139–43.
doi: 10.1002/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8
Wimazal F, Sperr WR, Kundi M, Meidlinger P, Fonatsch C, Jordan JH, et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res. 2001;25:287–94.
doi: 10.1016/S0145-2126(00)00140-5
Germing U, Hildebrandt B, Pfeilstöcker M, Nösslinger T, Valent P, Fonatsch C, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia. 2005;19:2223–31.
doi: 10.1038/sj.leu.2403963
García R, Hernández JM, Caballero MD, González M, Galende J, del Cañizo MC, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer. 1993;68:1227–31.
doi: 10.1038/bjc.1993.509
Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010;116:971–8.
doi: 10.1182/blood-2010-01-267302
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21:256–65.
doi: 10.1200/JCO.2003.08.005
Fanin R, Zuffa E, Fasola G, Damiani D, Gallizia C, Michieli MG, et al. Serum lactate dehydrogenase is an important risk determinant in acute lymphocytic leukemia. Haematologica. 1989;74:161–5.
pubmed: 2501169
Paltiel O, Rubinstein C, Or R, Nagler A, Gordon L, Deutsch L, et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transpl. 2003;31:565–9.
doi: 10.1038/sj.bmt.1703888
Bolwell B, Goormastic M, Andresen S. Durability of remission after ABMT for NHL: the importance of the 2-year evaluation point. Bone Marrow Transpl. 1997;19:443–8.
doi: 10.1038/sj.bmt.1700678
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transpl. 2008;14:418–25.
doi: 10.1016/j.bbmt.2008.01.008
Shouval R, Teper O, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, et al. LDH and renal function are prognostic factors for long-term outcomes of multiple myeloma patients undergoing allogeneic hematopoietic stem cell. Bone Marrow Transpl. 2020;55:1736–43.
doi: 10.1038/s41409-020-0829-1
Kalaycio M, Rybicki L, Pohlman B, Dean R, Sweetenham J, Andresen S, et al. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. Bone Marrow Transpl. 2007;40:753–8.
doi: 10.1038/sj.bmt.1705811
Mehta J, Gordon LI, Tallman MS, Winter JN, Evens AM, Frankfurt O, et al. Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? Bone Marrow Transpl. 2006;38:95–100.
doi: 10.1038/sj.bmt.1705388
Morishita T, Ichiki T, Okabe M, Kawaguchi Y, Ohbiki M, Osaki M, et al. Pretransplant increasing rate of lactate hydrogenase during treatment free period predicts transplant outcomes for patients not in remission. HemaSphere. 2019;3:336.
doi: 10.1097/01.HS9.0000561340.52350.57
Sivgin S, Ozenmis T, Kaynar L. Predictive value of pretransplant serum lactate dehydrogenase (LDH) levels for survival in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo HSCT). J Stem Cell Stem Res Ther. 2012;2:1.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
doi: 10.1182/blood-2014-01-552984
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Blaise D, Castagna L. Do different conditioning regimens really make a difference? Hematology Am Soc Hematol Educ Program. 2012;2012:237–45.. https://doi.org/10.1182/asheducation-2012.1.237 .
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transpl. 2010;45:1388–95.
doi: 10.1038/bmt.2009.359
Estey EH. Acute myeloid leukamia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93:1267–91.
doi: 10.1002/ajh.25214
Holbrook JJ, Liljas A, Steindel SJ, Rossmann MG. Lactate dehydrogenase. In: Boyer PD, editor. The Enzymes. 3rd ed. Vol. 11. New York, NY: Academic Press; 1975. p. 191–292.
Walaa Fikry ME. Lactate Dehydrogenase (LDH) as a prognostic marker in Acute Leukaemia “Quantitative Method”. J Blood Disord Transfus. 2017;8:1–7.
Sepulveda J. Chapter 9 - challenges in routine clinical chemistry analysis: proteins and enzymes. In: Dasgupta A, Sepulveda JL, editors. Accurate results in the clinical laboratory. San Diego: Elsevier; 2013. p. 131–48.
Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, et al. Pre-treatment C-reactive Protein(CRP) is a predictor for allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transpl. 2008;14:1209–16.
doi: 10.1016/j.bbmt.2008.08.004
Jordan K, Christensen I, Heilmann C, Sengeløv H, Müller KG. Pre-transplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation. Scand J Immunol. 2014;79:206–13.
doi: 10.1111/sji.12137
Pavlů J, Kew AK, Taylor-Roberts B, Auner HW, Marin D, Olavarria E, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115:4018–20.
doi: 10.1182/blood-2010-01-263624
Patel A, Szydlo R, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, et al. C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long term mortality. Br J Haematol. 2016;180:889–92.
doi: 10.1111/bjh.14454
Andersen J, Heilmann C, Jacobsen N, Nielsen C, Bendtzen K, Müller K. Differential effect on conditioning regimens on cytokine responses during allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37:635–40.
doi: 10.1038/sj.bmt.1705295
Shouval R, Fein JA, Labopin M, Cho C, Bazarbachi A, Baron F, et al. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry. Lancet Haematol. 2021;3:205–15.
doi: 10.1016/S2352-3026(20)30394-X